Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2015

View Archived Issues

[125I]EISB designed to detect Abeta plaques in brain and whole body

Anti-inflammatory and neuroprotective properties of TP-1008 in postischemic brain

Casein kinase II serum levels are possible biomarkers in prostate and colorectal cancers

Teva publishes results from phase IIb trial of TEV-48125 in episodic migraine

Exelixis begins rolling submission of NDA for cabozantinib for RCC

Moderna launches Caperna to develop personalized cancer vaccines

GeneOne files IND application for MERS vaccine GLS-5300

Hemispherx's MERS product receives positive opinion for E.U. orphan designation

MJFF funds Emulate to evaluate lung toxicity of LRRK2 inhibitors using Organs-on-Chips

AF-219 improves symptoms in patients with interstitial cystitis/bladder pain syndrome

Genentech advances GDC-0310 into clinical development

Applied Genetic Technologies' gene therapy product receives E.U. orphan drug designation

Shanghai Institute Materia Medica reports HDAC inhibitors

Lundbeck patents PDE1 inhibitors

Bristol-Myers Squibb describes Abeta production inhibitor

Lupin reports Nav1.7 modulators

Senju Pharmaceutical divulges VEGFR-2 inhibitors

Korean researchers describe ALK inhibitor more potent than crizotinib

GSK receives CHMP positive opinion to expand indication for Volibris

FDA clears IND application for Turing Pharmaceuticals' TUR-004, grants fast track status

FDA approves Iroko's Vivlodex for osteoarthritis pain

FDA advisory committee favors approval of AstraZeneca's lesinurad for hyperuricemia in gout

CHMP recommends approval of Imlygic for unresectable melanoma

FDA approves Strensiq for hypophosphatasia in children

EMA CHMP recommends approval of Cosentyx for ankylosing spondylitis and psoriatic arthritis

Researchers devise mouse model of nocturnal polyuria

Acceleron Pharma provides pipeline progress update

FDA approves Yondelis for liposarcoma and leiomyosarcoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...